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Abstract 
Natural killer cells are thought to influence the outcome of hematopoietic stem cell 
transplant (HSCT), impacting on relapse, overall survival, graft versus host disease 
and the control of infection, in part through the complex interplay between the large 
and genetically diverse killer immunoglobulin-like receptor (KIR) family and their 
ligands. This study examined the relationship between KIR gene content and clinical 
outcomes including the control of opportunistic infections such as cytomegalovirus in 
the setting of human leucocyte antigen (HLA)-matched sibling HSCT in an Australian 
cohort. The presence of the KIR B haplotype which contain more activating receptors 
in the donor, in particular centromeric B haplotype genes (Cen-B), was associated with 
improved overall survival of patients with acute myeloid leukemia (AML) undergoing 
sibling HSCT and receiving myeloablative conditioning. Donor Cen-B haplotype was 
also associated with reduced acute graft versus host disease grades II-IV whereas 
donor telomeric-B haplotype was associated with decreased incidence of CMV 
reactivation. In contrast, we were not able to demonstrate a reduced rate of relapse 
when the donor had KIR Cen-B, however relapse with a donor Cen-A haplotype was 
a competing risk factor to poor overall survival. Here we show that the presence of 
donor activating KIR led to improved outcome for the patient, potentially through 
reduced relapse rates and decreased incidence of acute GvHD translating to improved 
overall survival. 
  
Introduction 
 
Natural killer (NK) cells play a crucial a role in the control and elimination of tumours. 
Consistent with a role in anti-tumour immunity, studies have shown that antibody-
mediated depletion of NK cells can result in increased tumour burdens, typically in the 
context of transplantation.1-3 The activation of NK cells is controlled by a balance of 
activating and inhibitory signals that are transduced by an array of cell surface 
receptors many of which interact with Major Histocompatibility Class I (MHC-I) 
molecules.4 
In humans, NK cell surveillance of the expression of classical HLA class I proteins is 
largely mediated by killer cell immunoglobulin-like receptors (KIR), a large family of 
polymorphic receptors. The gene complex encoding KIR is found on chromosome 
19q13.4 within the Leukocyte Receptor Complex consisting of 14 genes and 2 
pseudogenes. At a population level, this complex is highly diverse with considerable 
variability in the gene content of KIR haplotypes as well as significant polymorphism 
within individual KIR genes.5,6 
 
The presence or absence of clusters of particular KIR genes has been used to define 
two broad haplotypes termed A and B. The A haplotypes have a relatively well-defined 
set of KIR genes including KIR2DL1, -2DL3, -3DL1 and -2DS4 of which only one, 
KIR2DS4 is an activating receptor. In contrast B haplotypes are far more varied in 
terms of gene content but typically possess more genes encoding activating receptors 
than A haplotypes. B haplotype genes include KIR2DS1, -2DS2, -2DS3, -2DS5, -
2DL2, -2DL5 and -3DS1, which may be in various combinations due to reciprocal 
recombination events.4,7,8 
In an attempt to understand how KIR/HLA interactions impact on the control of 
infection or cancer, numerous studies have correlated allotypic variation of either HLA 
class I or KIR with clinical outcomes, most notably perhaps in the setting of 
haematological malignancy. Ruggeri et al first observed that mismatching of KIR 
ligands between donor and recipient was associated with improved outcomes in 
patients receiving haploidentical hematopoietic stem cell transplantation (HSCT) for 
acute myeloid leukemia (AML).3,9 These data suggested that the lack of KIR ligands 
in transplant recipients resulted in reduced rates of relapse and graft versus host 
disease (GvHD). Further studies examining recipient and donor KIR haplotype showed 
evidence of protection against severe GvHD and improved survival in HLA-matched 
sibling transplants and unrelated HSCT when the donor had the B haplotype or 
presence of activating KIR.10-13 Activating KIR and KIR B haplotypes have also been 
implicated in the role of NK cell mediated control of cytomegalovirus (CMV) 
reactivation in HSCT, a major cause of morbidity.14,15 
While two broad types of haplotype have been identified, in an effort to identify the 
genes associated with clinical outcomes, a number of studies have focussed on 
centromeric (Cen) or telomeric (Tel) clusters of genes belonging to either the A or B 
haplotype. This further defines the KIR repertoire, as inhibitory receptors that 
recognise HLA-C C1 and C2 (based upon on the amino acid present at positions 77 
and 80) are located in the centromeric region whereas those that recognise Bw4 and 
A3/11 are within the telomeric region.11,16 Indeed using this approach patients 
receiving transplants from donors possessing clusters of centromeric genes from B 
haplotypes (Cen-B) have improved outcomes following unrelated HSCT than 
individuals that lack this cluster.11,17,18 Furthermore, renal transplant recipients that 
possess the telomeric cluster of the B genes (Tel-B) have been reported to maintain 
better control of CMV replication.19 
Many previous studies have been retrospective reports of myeloablative transplants. 
Non-myeloablative preparative regimens are often used for older patients and it is 
expected that the early balance between recipient and donor immunity will be 
markedly different from that in the myeloablative setting. In the study presented here, 
we have examined the relationship between KIR haplotype and the outcome of T-
replete HLA-matched sibling HSCT in an Australian cohort. We found improved 
survival, less aGVHD and decreased reactivation of CMV of patients when their donor 
had a B haplotype. This cohort was collected prospectively and includes patients that 
received myeloablative and reduced intensity conditioning. 
 
 
  
 
Methods 
 
Patient Demographics 
A total of 152 donor and recipient siblings were recruited from the Royal Adelaide 
Hospital, Adelaide, the Royal Melbourne and The Alfred Hospitals, Melbourne and 
Westmead Hospital in Sydney over the period 2002 - 2007. The study was approved 
by the human institutional review boards of all participating institutions. All donors and 
recipients provided informed consent to the study. 
 
KIR Genotyping 
DNA was extracted from 10 ml whole blood EDTA anticoagulated peripheral blood 
samples, taken prior to the commencement of therapy, using a modified salting out 
method.20 KIR genotyping was performed by PCR using multiplex sequence specific 
primers as previously described.21 KIR haplotypes were classified as the A haplotype 
carrying the KIR2DL1, -2DL3, -3DL1 and -2DS4 genes, all other combinations were 
denoted as the B haplotype. Combinations of KIR haplotype were assigned according 
to donor and then recipient haplotype (D-R), where Bx included BB and BA. Donor 
centromeric and telomeric haplotypes were assigned as previously described.11,22 
Briefly, KIR2DS2, -2DL1, -2DL2 and -2DL3 were considered centromeric and 
KIR3DL1/S1, -2DS5, -2DS1 and -2DS4 were considered telomeric. Combinations of 
these gave the haplotypes as centromere (Cen) or telomere (Tel) AA, BA or BB. As 
only 4 donors had the Cen BB haplotype and 10 with Tel BB, the BA and BB 
haplotypes were combined and analysed as Bx. 
Clinical data was reviewed to determine day of death, relapse, CMV reactivation, 
GvHD or last known outpatient appointment. Data was analysed by GraphPad Prism 
6 using Kaplan-Meier survival curves and compared using the Log Rank (Mantel-Cox) 
test. The result was considered significant if P<0.05. The Fine and Gray statistical test 
implemented in R version 3.4.1 (cmprsk package, version 2.2-7) was used to examine 
associations between haplotypes, competing risks and the cumulative incidence of 
death.23 Multivariate analysis for relapse free survival was performed using Cox-
proportional hazard model implemented in R version 3.4.1 (survival package, coxph 
function, version 2.41-3). 
  
 
 
 
 
 
 
Results 
Transplant Characteristics 
Patients were consecutively recruited to the study and considered eligible if they were 
undergoing HSCT for hematological malignancies or severe aplastic anaemia and 
over 18 years of age. Patients who were undergoing T-depleted HSCT or were 
Hepatitis B, C or HIV positive by serology or DNA testing were excluded. Transplant 
characteristics of those with complete clinical data (n=145) are summarised in Table 
1. Ninety-five men and 50 women received hematopoietic stem cell transplants 
donated by an HLA-matched sibling. Eighty-five patients received myeloablative 
conditioning and 60 reduced intensity conditioning (RIC). The majority of patients 
received peripheral blood as the source of the stem cells and all were T-cell replete 
with the median time of follow-up being 2 years (9 days - 4.1 years). Of the 145 
patients, 69 (47%) had been diagnosed with AML, the second largest group were 
those diagnosed with Non-Hodgkin Lymphoma (13%). 
Seventy-eight percent of recipients (n=114) received GvHD prophylaxis for consisting 
of cyclosporine A/tacrolimus and short course methotrexate (MTX). CMV 
management involved either a prophylactic strategy using gancyclovir or oral 
valacyclovir or a pre-emptive strategy, involving weekly monitoring of blood for CMV 
DNA and treatment with gancyclovir or foscarnet where appropriate. 
Multivariate analysis did not reveal any significant associations with relapse free 
survival when disease diagnosis, age at transplant, CMV reactivation or GvHD were 
considered (Supplementary Figure 1). There was a trend towards more males and the 
type of conditioning (RIC) received and relapse, however this did not reach statistical 
significance. 
 
Donor KIR Haplotype alone was not associated with improved survival 
To determine if there was a relationship between KIR haplotype and survival after 
sibling allogeneic HSCT, the KIR gene content of both donors and recipients was 
assessed and used to infer the associated KIR haplotypes in a cohort of 145 transplant 
recipients. Without disease stratification, there were no significant differences in 
overall survival associated with the presence of distinct KIR haplotypes in the donor 
(Figure 1A). Similarly, when limited to patients receiving transplants for AML, there 
was also no significant difference in relapse rates based on donor KIR haplotype either 
when all patients with AML were assessed or when the analyses were limited to those 
who received myeloablative conditioning (Figure 1A). 
 
The presence of donor Cen-B genes was associated with improved overall 
survival. 
While there was no significant association between the B haplotype and overall 
survival in this cohort, previous studies had suggested that the centromeric cluster of 
the B haplotypes was more strongly associated with survival in a number of contexts. 
Furthermore, in our patient cohort, the presence in the donor of KIR2DS2, the only 
activating KIR within the centromeric end of B haplotypes, was also associated with 
significantly improved overall survival in both the AML cohort (P = 0.03) and those 
AML patients that received myeloablative conditioning (P=0.01) (Figure 1B). 
 
Consequently, the cohort was stratified based on the presence of donor-derived 
centromeric or telomeric genes. Again, when the entire cohort was assessed, there 
were no significant differences in outcomes associated with presence of donor derived 
B genes, irrespective of whether they were encoded within the centromeric or 
telomeric region of the locus. However, for patients with AML, the presence of 
centromeric genes of B haplotypes (Cen-B) was associated with improved overall 
survival (P=0.01) (Table 2 and Figure 2A, centre). When limited to patients who 
received myeloablative conditioning, this association was also evident (P=0.01) (Table 
2 and Figure 2A, right). 
 
The presence of Cen-B genes was not associated with reduced rates of relapse. 
To better understand the mechanisms responsible for the improved overall survival in 
patients receiving transplants from donors with Cen-B genes, the proportion of patients 
who relapsed was also assessed. As with overall survival, there was no significant 
association between the presence of Cen-B genes and relapse when the entire cohort 
was assessed. Furthermore, there was no significant reduction in the number of AML 
patients who experienced relapse associated with presence of Tel-B or Cen-B genes, 
or when the analyses were focused on patients who had received only myeloablative 
conditioning (Table 2 and supplementary figure 2). Similarly, comparison of the 
frequency of individual KIR genes in patients who relapsed compared to those who 
did not showed no marked differences with the possible exception of KIR2DS3 which 
was found in higher frequency in patients who did not relapse (data not shown). 
Cumulative incidence of death was considered with relapse as a competing risk. 
Significant associations were found when the donor had a Cen-B haplotype with 
improved overall survival in patients diagnosed with AML (P = 0.03) and those with 
AML and receiving myeloablative conditioning (P = 0.05) (Figure 3). Thus, the data 
suggests that the improved overall survival associated with Cen-B genes may be 
linked to reduced levels of relapse. 
 
No improvement in the incidence of CMV reactivation with the presence of KIR 
Cen-B genes 
In the absence of an association between the presence of Cen-B genes and disease 
relapse, we next considered whether the presence of these genes was associated 
with better control of cytomegalovirus replication, a common complication in HSCT 
where both primary infection and reactivation are associated with adverse 
outcomes.24 Of the 145 recipients for which full clinical data was available, 97 were 
CMV seropositive prior to transplant. No seronegative patients had evidence of CMV 
viremia after transplantation. In patients that were seropositive for CMV at diagnosis, 
there was no significant decrease in the timing or frequency of CMV reactivation that 
could be linked to the presence of Cen-B haplotypes. In contrast, CMV reactivation in 
patients that received a transplant from donors that were Tel-B/x was markedly less 
than those receiving a transplant from a donor that possessed the A haplotype 
(P=0.02) (Table 2, supplementary figure 3). 
All recipients either received a suppressive prophylactic treatment or pre-emptive 
treatment to control CMV. When stratified according to CMV treatment and donor KIR 
haplotype, only those receiving pre-emptive prophylaxis exhibited any significant 
differences, with those having an AA donor being associated with increased CMV 
reactivation relative to those receiving Tel-B (P=0.03) (Table 2, supplementary figure 
3). 
CMV reactivation was considered as a competing risk by cumulative incidence of 
death, without stratification for IgG positivity or prophylaxis. Cen-B was associated 
with improved survival in patients with AML (P = 0.012) and AML with myeloablative 
conditioning (P = 0.018) however Tel-B was associated with poor survival when the 
entire cohort was considered (P = 0.004) (Supplementary figure 4). 
 
Donor KIR Cen-B was protective against aGvHD in patients with AML. 
A similar approach was taken to determine if KIR haplotype had an effect on the 
occurrence of GvHD. When the effect of KIR haplotype on GvHD was considered for 
the entire cohort, for those treated for AML or according to pre-transplant conditioning 
there were no significant differences. 
Acute GvHD (aGvHD) was defined as grades II-IV aGvHD up to day 50 post-
transplant. When the effect of donor KIR haplotype on aGvHD was considered for the 
entire cohort, no significant differences were noted (Table 2). However, when this was 
stratified to include only those receiving treatment for AML, a significant difference was 
seen (P = 0.04), with an increased proportion of recipients receiving grafts from Cen-
A donors having aGvHD (Table 2 and supplementary figure 5A). 
Cumulative incidence of death was considered with GvHD as a competing risk, without 
stratification of grade and considered up to 100 days post-transplant. GvHD was also 
a significant competing risk factor to overall survival when the donor had a Tel-B 
haplotype for the entire cohort (P = 0.01) and AML (P = 0.02) (Supplementary figure 
6). 
 
 
 
 
 
Discussion 
In this study, donor and recipient sibling HSCT pairs were prospectively recruited from 
four major transplant hospitals in Australia, to investigate the role of KIR in transplant 
outcome. Prior studies examining the role of NK cell mediated alloreactivity and the 
outcome of HSCT have yielded conflicting data.9,17,25-28 Improvement in HSCT 
outcome by alloreactive donor NK cells was first reported in the haploidentical setting 
where decreased relapse rates and a protective effect against GvHD were observed.3 
Since then, many groups have sought to correlate KIR haplotype with the outcome of 
HSCT. As with other studies 11,29-31, when our entire cohort of MHC-matched cases 
was examined no significant associations of either donor or recipient KIR haplotype 
were evident with overall survival, relapse free survival or GvHD. However, when just 
those receiving treatment for AML were examined, statistically significant associations 
were found. 
Significant associations were found with clinically relevant aGvHD and overall survival 
when the donor had both the AA haplotype and Cen-A KIR, and therefore limited 
numbers of activating KIR. All transplants were T cell replete and this may be a 
confounding factor, as when T cells are included in the graft this can affect the 
reconstitution of NK cells.32,33 A proposed mechanism for the beneficial effect of NK 
cell alloreactivity in the setting of HSCT is the ability to lyse recipient antigen presenting 
cells (APCs) that might otherwise prime donor derived T cells to induce GvHD.3 The 
presence of only one activating KIR or indeed stronger inhibitory receptors that are 
associated with A haplotypes 34 may limit their capacity to lyse recipient APCs resulting 
in inferior survival due to increased aGvHD. Consistent with this, studies in the 
haploidentical setting have found that the presence of the activating KIR2DS1 on NK 
cells is associated with an enhanced capacity to kill mature allogeneic myelomonocytic 
dendritic cells.35 These same studies also found increased lysis of T cell blasts by NK 
cells expressing KIR2DS1 compared with those that lacked KIR2DS1. Thus, an 
additional mechanism by which donors with B haplotypes might limit GvHD, is through 
direct NK recognition of activated recipient reactive T cells. 
The impact of KIR haplotype on survival in HSCT prompted an analysis of the effect 
of KIR haplotype on CMV reactivation. Patients who received stem cells from AA 
donors had significantly more CMV reactivation than those from Bx donors, but this 
effect was limited to those that received myeloablative conditioning and pre-emptive 
treatment. Similar results are reported in the myeloablative setting in both T-depleted 
or non-T-depleted studies and sibling or unrelated transplant cohorts.14,15 In contrast, 
another unrelated and T depleted study has reported no effect of KIR haplotype on 
CMV reactivation.27 This advantage was limited to Tel-B and to a subset of those with 
CMV reactivation, in contrast to overall survival and aGvHD where this was a Cen-B 
effect. Together with the mixed results in the cumulative incidence of death analyses, 
this may suggest that KIR haplotype in relation to CMV reactivation is not an important 
driver of survival in this cohort and potentially that the immune mechanisms for CMV 
control are different to those for GvHD. 
 
 
Despite studies to the contrary we were unable to find any direct association between 
KIR haplotype and reduced relapse rates notwithstanding also examining missing 
ligands and the number of B haplotype genes as described in other studies.11,17,18,26 
However, we did demonstrate that significantly improved overall survival with donor 
Cen-B when relapse was considered as a competing risk. These mixed results may 
be due to heterogeneity of this cohort and small sample size. While samples were 
collected prospectively from all eligible patients over a period of four years, it fell short 
of the planned 250 sibling pairs, impacting on the ability to obtain adequate power and 
this may have affected the statistical analysis. Differences among conditioning 
protocols and post-transplant treatment may also contribute to the discrepancies seen 
between NK alloreactivity and survival across cohorts. While similar trends for were 
evident for patients undergoing RIC, small numbers in this study restricted meaningful 
analysis of outcomes. Of interest, relapse rates for the entire cohort was 20% and in 
the AML group was 23% whereas generally the relapse rates for AML patients exceed 
40%.36 Multivariate analysis did not reveal any independent factors for improved 
relapse-free survival. Although limited sample size makes multivariate analysis difficult 
to interpret, these figures would suggest that this is lower than expected perhaps 
reflecting the prospective nature and best practice of this cohort at the time of the 
study. 
While the initial studies examining HSCT outcome in KIR ligand mismatched recipients 
were encouraging, the interpretation of this data has become increasingly complex. 
The previous understanding of the range of HLA-C ligands for KIR2DL2/3 was 
somewhat limited, excluding group 2 HLA-C alleles such as HLA-Cw6 that have been 
shown to function as ligands for KIR2DL2.37 The promiscuous nature of KIR2DL2 has 
been demonstrated through binding to a number of HLA-C alleles while allelic diversity 
has also been shown to impact their specificity.34,38,39 While the ligands for activating 
KIR remain poorly characterised in general, KIR2DS1 has been demonstrated to 
mediate alloreactivity while KIRDS2 also appears to recognise discrete subsets of HLA 
class I allotypes.35,40-43 KIR3DS1 has been shown to reduce mortality and despite 
structural similarity to 3DL1 appears to recognise the non-classical molecule HLA-
F.40,44,45 Secondly, it is now evident that MHC class I expression impacts on the 
function of NK cells via licensing.34,46-48 Consequently, the altered environment 
present within the allogeneic recipient may itself impact the composition of the NK cell 
compartment, being shaped by an education process distinct from that of T cells but 
nevertheless important in the acquisition of effector function by mature NK cells.49 
While differences in HSCT protocols may continue to confound results, the data 
presented in this limited, small study add to reports that B haplotype genes are 
associated with improved outcomes following HSCT.10,11,31,50 Furthermore, 
centromeric and telomeric clusters were associated with improved overall survival and 
decreased incidence of CMV reactivation respectively in patients diagnosed with AML. 
A greater understanding of the contribution of these distinct arms of the KIR haplotype 
awaits larger scale studies with high-resolution genetics. 
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Figure Legends 
Figure 1. Donor KIR 2DS2/2DL2 was associated with improved survival in patients 
with AML. 
Kaplan Meier analysis with log-rank statistic. Donor KIR genes with assigned to AA or 
Bx (BB and BA) haplotypes (panel A) or the presence or absence of KIR2DS2/2DL2 
(panel B) and the analysis was determined for entire cohort (left), for AML patients 
only (centre) and those receiving myeloablative conditioning (right). AA haplotype is 
shown in red and Bx (BB and BA) is shown in black. The presence of KIR2DS2/2DL2 
is shown in blue and the absence in purple. 
Figure 2. Overall survival was significantly improved in AML patients receiving a 
HSCT from a sibling with KIR Cen-B haplotype. 
Kaplan Meier analysis of overall survival with log rank statistic. Donor KIR genes were 
assigned to centromeric (A) or telomeric (B) haplotypes and the analysis was 
determined for the entire cohort (left), for AML patients only (centre) and those 
receiving myeloablative conditioning (right). AA haplotype is shown in red and Bx (BB 
and BA) in black. 
 
Figure 3. Significant improvement in overall survival with donor Cen-B with relapse as 
a competing risk in AML patients. 
Fine and Grey statistical method with relapse as a competing risk to overall survival. 
Donor KIR genes were assigned to centromeric (A) or telomeric (B) haplotypes and 
the analysis was determined for the entire cohort (left), for AML patients only (centre) 
and those receiving myeloablative conditioning (right). AA haplotype is shown in solid 
line and Bx (BB and BA) in dashed line. The number at risk in each group is shown 
with 0 = alive, 1 = death and 2 = relapse. 
 
Supplementary Figure Legends 
 
Supplementary Figure 1. Multivariate analysis of relapse free survival. Multivariate 
analysis of relapse free survival using Cox proportional hazard modelling in R. The 
following variables were considered: disease status, type of conditioning, CMV 
reactivation, GvHD (any grade), recipient sex and age at transplant (>50 years or 
below). 
 
Supplementary Figure 2. Donor KIR haplotype did not impact on the inncidence of 
relapse in recipients undergoing HSCT. 
Kaplan Meier analysis of day to relapse with log rank statistic. Donor KIR genes were 
assigned to centromeric (A) or telomeric (B) haplotypes and the analysis was 
determined for the entire cohort (left), for AML patients only (centre) and those 
receiving myeloablative conditioning (right). AA haplotype is shown in red and Bx (BB 
and BA) in black. 
 
Supplementary Figure 3. The presence of donor KIR Tel-B genes in conjunction with 
pre-emptive CMV treatment was significantly associated with decreased CMV 
reactivation. 
Kaplan Meier analysis with log rank statistic. CMV reactivation was monitored until day 
100 post transplant. Donor KIR genes were assigned to centromeric (A) or telomeric 
(B) haplotypes and the analysis was determined for patients that were IgG positive for 
CMV at diagnosis(left), IgG positive and receiving pre-emptive treatment (centre) and 
IgG positive and on the prophylaxis treatment arm (right). AA haplotype is shown in 
red and Bx (BB and BA) in black. 
 
Supplementary Figure 4. Cumulative incidence of death with CMV as a competing 
risk. 
Fine and Grey statistical method with CMV as a competing risk to overall survival. 
Donor KIR genes were assigned to centromeric (A) or telomeric (B) haplotypes and 
the analysis was determined for the entire cohort (left), for AML patients only (centre) 
and those receiving myeloablative conditioning (right). AA haplotype is shown in solid 
line and Bx (BB and BA) in dashed line. The number at risk in each group is shown 
with 0 = alive, 1 = death and 2 = CMV. 
 
Supplementary Figure 5. Severe aGVHD was significantly improved when the donor 
had KIR Cen-B haplotype in patients with AML. 
Kaplan Meier analysis with Gehan-Breslow-Wilcoxon test. Severe aGvHD was defined 
as grades II-IV within the first 50 days after HSCT. Donor KIR genes were assigned 
to centromeric (A) or telomeric (B) haplotypes and the analysis was determined for the 
entire cohort (left), for AML patients only (centre) and those receiving myeloablative 
conditioning (right). AA haplotype is shown in red and Bx (BB and BA) in black. 
 
Supplementary Figure 6. Cumulative incidence of death with GvHD as a competing 
risk. 
Fine and Grey statistical method with GvHD (any grade to day 100) as a competing 
risk to overall survival. Donor KIR genes were assigned to centromeric (A) or telomeric 
(B) haplotypes and the analysis was determined for the entire cohort (left), for AML 
patients only (centre) and those receiving myeloablative conditioning (right). AA 
haplotype is shown in solid line and Bx (BB and BA) in dashed line. The number at 
risk in each group is shown with 0 = alive, 1 = death and 2 = GvHD 
 Conditioning 
 Myeloablative Reduced Intensity 
 (n=86) (n=59)    
 
Mean age at transplant 
(years) 39.4 (19-58) 51 (19-64) 
 Recipient sex 55 M, 31 F 39 M, 20 F 
 Disease   
 
Acute lymphoblastic 
leukemia 11 0 
 Acute myeloid leukemia 44 25 
 Chronic lymphoid leukemia 0 3 
 Chronic myeloid leukemia 7 1 
 Hodgkin lymphoma 1 5 
 Myelodysplastic syndrome 2 1 
 Multiple myeloma 1 12 
 Non-Hodgkin lymphoma 11 8 
 Aplastic anemia 5 0 
 Other 4 4 
 Conditioning regimen   
 Busulphan plus   
 cyclophosphamide 22 0 
 Cyclophosphamide plus TBI 54 0 
 Etoposide plus TBI 8 0 
 Fludarabine plus   
 cyclophosphamide 0 27 
 Fludarabine plus melphalan 0 24 
 ATG pus cyclophosphamide 1 0 
 Melphalan 0 5 
 Low dose TBI 0 4 
 Immunosuppresion   
 Cyclosporin/tacrolimus plus   
 Methotrexate 69 45 
 
Cyclosporin plus 
mycophenolate   
 mofetil 0 6 
 Cyclosporin 14 4 
 Other 2 5 
 CMV Prophylaxis   
 Pre-emptive 61 32 
 Suppressive 21 28 
 Unknown 3 0    
 
Table 1 Transplant characteristics  
Myeloablative total body irradiation (TBI) consisted of doses of 12 to 13.2 Gy 
while low dose was 2 Gy. 
  
 A              
       Overall survival     
    Centromere     Telomere    
A r t i c l e 
  % survival proportion % survival proportion 
 n= AA  Bx  P = AA Bx P = 
AML, RIC 25 48.1  27.4  0.35 32.8 40 0.49  
 Entire cohort 145 45.6 56.3  0.53 51.2 51.3 0.12 
 AML only 69 46.3 53.6  0.01 56.5 43.4 0.81 
               
 AML, myeloablative 44 52.2 47.7  0.01 54.5 45.4 0.96 
               
 AML, RIC 25 40.04 62.5  0.48 47.6 60 0.70 
 B              
       Relapse free survival     
    Centromere     Telomere    
   % survival proportion % survival proportion 
  n= AA  Bx  P = AA Bx P = 
 Entire cohort 145 33.2 32.2  0.54 33.8 27 0.98 
 AML only 69 31.6 24.0  0.39 26.5 30.1 0.50 
 AML, myeloablative 44 23.1 21.9  0.63 23.0 24.3 0.70 A c c e p t e d 
              
C              
      aGVHD (grades II‐IV)     
           
    Centromere     Telomere    
   % survival proportion (day 50) % survival proportion (day 50) 
  n= AA  Bx   P = AA Bx  P = 
 Entire cohort 145 36.3 23.8  0.09 31.9 27.9 0.75 
 AML only 69 43.1 19.6  0.04 35.4 23.3 0.33 
               
 AML, myeloablative 44 42.3 17.6  0.13 35.8 22.3 0.59 
 AML, RIC 25 50 20  0.11 35.3 22.2 0.40 
 D              
       CMV Reactivation     
    Centromere     Telomere    
   % survival proportion (day 100) % survival proportion (day 100) 
  n= AA  Bx  P = AA Bx P = 
 IgG positive 97 51.1 42.2  0.28 58.3 36.7 0.02 
             
 IgG pos, Pre‐emptive arm 53 55.1 55  0.79 73 44.4 0.03 
             
 IgG pos, prophylaxis arm 44 42.8 30  0.28 40.9 27.2 0.26 
 
 
Table 2. Summary of Outcomes 
 
Summary of Kaplan Meier analyses with log rank statistic for A - overall survival, B – 
relapse free survival, C – severe graft versus host disease and D-CMV reactivation 
according to donor KIR centromere or telomere haplotype. P <0.05 was considered 
significant and underlined.  
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